Jennifer L. Taylor-Cousar

Poster(s):

• (693) A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 2 Through 5 Years of Age with Cystic Fibrosis and at Least One F508del Allele
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (694) Greater Reductions in Sweat Chloride with CFTR Modulator Use are Associated with Improved Clinical Outcomes
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET